{
    "organizations": [],
    "uuid": "d6def4bdb85d3604efebb2784cbcd8529223451e",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-concert-pharma-says-intends-to-com/brief-concert-pharma-says-intends-to-complete-evaluation-and-advance-ctp-692-into-clinical-development-by-2018-end-idUSFWN1QI1JG",
    "ord_in_thread": 0,
    "title": "BRIEF-Concert Pharma Says Intends To Complete Evaluation And Advance CTP-692 Into Clinical Development By 2018 End",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 28 (Reuters) - Concert Pharmaceuticals Inc:\n* CONCERT PHARMACEUTICALS INC SAYS INTENDS TO COMPLETE PRECLINICAL EVALUATION AND ADVANCE CTP-692 INTO CLINICAL DEVELOPMENT BY YEAR-END 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-01T05:26:00.000+02:00",
    "crawled": "2018-03-01T21:11:11.021+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "concert",
        "pharmaceutical",
        "inc",
        "concert",
        "pharmaceutical",
        "inc",
        "say",
        "intends",
        "complete",
        "preclinical",
        "evaluation",
        "advance",
        "clinical",
        "development",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}